Transition Information | Cytiva, formerly GE Healthcare Life Sciences

Last Updated: 30 September 2020

Notification: Important information for Cytiva suppliers about Cytiva system changes: Click Here.

Transition Information

As announced on April 1, 2020, the Danaher Corporation finalized its purchase of GE Healthcare Life Sciences’ business units consisting of BioProcess, Cell & Gene Therapy and Genomics & Cellular Research. Now Cytiva, we are part of Danaher’s Life Sciences platform. We have relationships with many suppliers and vendors who are being notified of the change in corporate structure.

We want to be sure that business continues smoothly between us. This page is intended to help you navigate through the actions necessary to keep business moving as smoothly as possible. We will update this page as more information becomes available.

In some instances, the legal entity that the Cytiva business has contracted through has or will be changing. In other cases, the legal entity that the Cytiva business has contracted through is not changing, but the ownership of the legal entity is changing, either through an internal restructuring and/or with the sale to Danaher.

What is not changing

We remain focused on being a great partner to you, our suppliers and vendors. Here is a list of what WILL NOT CHANGE as a result of transition steps:

Manufacturing processes.
In the case of indirect procurement and accounts payable, Cytiva will continue to leverage GE Healthcare systems.
If you are doing business with any other GE Healthcare business that is not BioProcess, Cell and Gene Therapy, or Genomics and Cellular Research, then you continue business as in the past.

Changes you need to make

Look out for notices about changes in contracting party or invoicing details. Click here (updated 8.07.2020) to see the table which lists which legal entities are changing and when. Any receipted orders or releases that are in the process of payment might require a re-issue of a purchase order. Please be on the lookout if a PO is reissued to you.

Invoices addressed to the incorrect legal entity may be rejected and you may need to work with requestor to get details of the new PO to be able to reissue the invoices. You may be notified to update invoicing and bank account information to reflect the new legal entity where applicable.